Allogeneic hematopoietic stem cell transplantation in China: Where we are and where to go

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Lv, Meng ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Allo HSCT; China; Elderly patients; GVHD; Haploidentical; Relapse

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DACLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SEMUSTINE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHINA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; EVIDENCE BASED PRACTICE; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; RELAPSE; REVIEW; AGE; ALLOTRANSPLANTATION; BIOLOGICAL MODEL; ETHNOLOGY; EVALUATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY;

AGE FACTORS; CHINA; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MODELS, BIOLOGICAL; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84858253671     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-10     Document Type: Review

References (63)

1. Allogeneic bone marrow transplantation for the treatment of leukemia. Lu DP, Guo NL, Jin NR, Zheng H, Lu XJ, Shi Q, Shan FX, Jiang B, Tang H, Liu MY, Chin Med J (Engl) 1990 103 125 130 (Pubitemid 20300860)
2. Current status and development of hematopoietic stem cell transplantation in China: a report from Chinese Hematopoietic Stem Cell Transplantation Register Group. Xu LP, Huang XJ, Chin Med J (Engl) 2011 124 2548 2555
3. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides, 2011. Pasquini MCWZ, http://www.cibmtr.org
4. Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase. Jiang Q, Xu LP, Liu DH, Liu KY, Chen SS, Jiang B, Jiang H, Chen H, Chen YH, Han W, et al. Blood 2011 117 3032 3040 10.1182/blood-2010-09- 308510 21252092
5. Current status of haploidentical stem cell transplantation for leukemia. Huang XJ, J Hematol Oncol 2008 1 27 10.1186/1756-8722-1-27 19117511
6. HLA-haploidentical stem cell transplantation for hematologic malignancies. Fuchs EJ, Huang XJ, Miller JS, Biol Blood Marrow Transplant 2010 16 57 S63 10.1016/j.bbmt.2009.10.032 19892024
7. Haploidentical hematopoietic transplantation: current status and future perspectives. Reisner Y, Hagin D, Martelli MF, Blood 2011 118 6006 6017 10.1182/blood-2011-07-338822 21921045
8. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, Felicini R, Falcinelli F, Velardi A, Ruggeri L, et al. J Clin Oncol 2005 23 3447 3454 10.1200/JCO.2005.09.117 15753458
9. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, et al. Blood 2011 118 282 288 10.1182/blood-2011-03-344853 21527516
10. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, Chute J, Smith C, Gong JZ, Lagoo A, et al. J Clin Oncol 2007 25 690 697 10.1200/JCO.2006.07.0953 17228020 (Pubitemid 350002925)
11. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC, Blood 2008 112 2232 2241 10.1182/blood-2008-03-143636 18617635
12. Results of a Phase II Study of Haploidentical Hematopoietic Cell Transplantation (HHCT) in Adults Using Reduced Intensity Conditioning and CD3/CD19-Depleted Grafts: clinical outcome and immune reconstitution. Federmann B, Bornhauser M, Kordelas L, Beelen DW, Stuhler G, Schwerdtfeger R, Stelljes M, Behre G, Christopeit M, Faul C, et al. ASH Annual Meeting Abstracts 2009 114 1203
13. Haploidentical hematopoietic stem cell transplantation to adults with hematologic malignancies: analysis of 66 cases at a single Japanese center. Kurokawa T, Ishiyama K, Ozaki J, Yamashita Y, Iwaki N, Saito C, Arahata M, Kaya H, Yoshida T, Int J Hematol 2010 91 661 669 10.1007/s12185-010-0561-5 20390388
14. Long Term Follow-up of Haploidentical Hematopoietic Stem Cell Transplantation without in Vitro T Cell Depletion for the Treatment of Hematological Malignancies: 9-Year Experience of a Single Center. Huang XJ, ASH Annual Meeting Abstracts 2011 118 839
15. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Lee KH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, et al. Blood 2011 118 2609 2617 10.1182/blood-2011-02-339838 21715313
16. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Huang W, Li H, Gao C, Bo J, Wang Q, Zhao Y, Jing Y, Wang S, Zhu H, Dou L, et al. Transfusion 2012 doi: 10.1111/j.1537-2995.2011.03478.x
17. A brief introduction of the Chinese Marrow Donor Program. Hong JL, Hong Kong Med J 2009 15 45 47 20393214
18. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao ZY, Zhang YC, et al. Bone Marrow Transplant 2006 38 291 297 10.1038/sj.bmt.1705445 16883312 (Pubitemid 44203779)
19. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, et al. Blood 2006 107 3065 3073 10.1182/blood-2005-05-2146 16380454
20. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H, Yu-Hong C, Jing-Zhi W, Yao C, Xiao-Hui Z, et al. Ann Med 2008 40 444 455 10.1080/07853890801908903 18608121
21. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, Yu-Hong C, Wei H, Jing-Zhi W, Yao C, et al. clin cancer res 2009 15 4777 4783 10.1158/1078-0432.CCR-09-0691 19584148
22. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX, Huang XJ, Biol Blood Marrow Transplant 2011 17 821 830 10.1016/j.bbmt.2010.08.023 20831895
23. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD. Guo M, Sun Z, Sun QY, Han Q, Yu CL, Wang DH, Qiao JH, Chen B, Sun WJ, Hu KX, et al. Biol Blood Marrow Transplant 2009 15 930 937 10.1016/j.bbmt.2009.04.006 19589482
24. The efficacy and safety of mismatched hematopoietic stem cell transplantation for treatment of severe aplastic anemia. Han W, Huang XJ, Liu KY, Xu LP, Liu DH, Chen H, Zhang XH, Chen YH, Wang FR, Wang Y, Zhonghua Nei Ke Za Zhi 2011 50 287 290 21600145
25. Allelic and haplotypic diversity of HLA-A, -B, -C, -DRB1, and -DQB1 genes in the Korean population. Lee KW, Oh DH, Lee C, Yang SY, Tissue Antigens 2005 65 437 447 10.1111/j.1399-0039.2005.00386.x 15853898 (Pubitemid 40592937)
26. Current status of Japan marrow donor program (JMDP) and its roles in international cooperation. Okamoto S, Int J Hematol 2002 76 Suppl 1 310 311 12463593
27. HLA class I (A, B, C) and class II (DRB1, DQA1, DQB1, DPB1) alleles and haplotypes in the Han from southern China. Trachtenberg E, Vinson M, Hayes E, Hsu YM, Houtchens K, Erlich H, Klitz W, Hsia Y, Hollenbach J, Tissue Antigens 2007 70 455 463 10.1111/j.1399-0039.2007.00932.x 17900288 (Pubitemid 350075785)
28. Study of HLA polymorphism in the 6965 Han bone marrow registry donors. Wu GG, Deng ZH, Gao SQ, Cheng LH, Jin SZ, Zhou D, Li Z, Zou HY, Zhang X, Wei TL, et al. Zhonghua Xue Ye Xue Za Zhi 2004 25 473 477 15555263
29. HLA DNA sequence variation among human populations: molecular signatures of demographic and selective events. Buhler S, Sanchez-Mazas A, PLoS One 2011 6 14643 10.1371/journal.pone.0014643 21408106
30. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Jun HX, Jun CY, Yu ZX, Haematologica 2004 89 1517 1524 15590404
31. A direct comparison of immunological characteristics of granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts and G-CSF-mobilized peripheral blood grafts. Jun HX, Jun CY, Yu ZX, Haematologica 2005 90 715 716 15921400 (Pubitemid 40780905)
32. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Huang XJ, Chang YJ, Zhao XY, Transpl Immunol 2007 17 193 197 10.1016/j.trim.2006.10.002 17331846
33. Rabbit ATG but not horse ATG promotes expansion of functional CD4 + CD25highFOXP3+ regulatory T cells in vitro. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS, Blood 2008 111 3675 3683 10.1182/blood-2008-01-130146 18250226
34. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al. Science 2002 295 2097 2100 10.1126/science.1068440 11896281 (Pubitemid 34229476)
35. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP, Leukemia 2007 21 848 851 17268518
36. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Chang YJ, Zhao XY, Huang XJ, Biol Blood Marrow Transplant 2008 14 323 334 10.1016/j.bbmt.2007.12.497 18275899 (Pubitemid 351218202)
37. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, Zhang L, Wang Y, Liu L, Wu K, et al. Blood 2011 117 5257 5260 10.1182/blood-2010-12-326322 21403128
38. Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. Diamond HR, Ornellas MH, Orfao A, Gomes BE, Campos MM, Fernandez TS, da Silva RI, Alves G, Lage C, da Silva DA, et al. J Hematol Oncol 2011 4 39 10.1186/1756-8722-4-39 21951951
39. Immunomodulatory strategies for relapse after haploidentical hematopoietic stem cell transplantation in hematologic malignancy patients. Huang XJ, Best Pract Res Clin Haematol 2011 24 351 358 10.1016/j.beha.2011.04. 002 21925088
40. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, et al. Blood 1995 86 2041 2050 7655033
41. Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect. Huang XJ, Wang Y, Liu DH, Xu LP, Liu KY, Chen H, Chen YH, Han W, Shi HX, Bone Marrow Transplant 2009 44 309 316 10.1038/bmt.2009.26 19234512
42. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Huang X, Guo N, Ren H, Zhang Y, Gao Z, Lu D, Chin Med J (Engl) 2003 116 736 741 (Pubitemid 36701860)
43. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Haematologica 2007 92 414 417 10.3324/haematol.10570 17339194 (Pubitemid 350143554)
44. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Huang XJ, Liu DH, Xu LP, Chen H, Han W, Liu KY, Lu DP, Leukemia 2006 20 365 368 10.1038/sj.leu. 2403995 16331281 (Pubitemid 43148683)
45. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. Huang XJ, Liu DH, Liu KY, Xu LP, Chen YH, Wang Y, Han W, Chen H, J Clin Immunol 2008 28 276 283 10.1007/s10875-007-9166-z 18204965
46. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ, Blood 2012 doi:10.1182/blood-2011-09-380386
47. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia-feasibility and safety study. Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH, Han W, Shi HX, Liu KY, J Clin Immunol 2008 28 390 397 10.1007/s10875-008-9193-4 18347959
48. IFN-gamma promotes graft-versus-leukemia effects without directly interacting with leukemia cells in mice after allogeneic hematopoietic cell transplantation. Yang Y, Wang H, Yu H, Yeap BY, Liang T, Wang G, Cheng T, Yang YG, Blood 2011 118 3721 3724 10.1182/blood-2010-05-283887 21835954
49. Low-dose MTX combined with low-dose methylprednisolone as a first-line therapy for the treatment of acute GVHD: safety and feasibility. Wang Y, Xu LP, Liu KY, Liu DH, Wang J, Chen H, Chen YH, Han W, Huang XJ, Bone Marrow Transplant 2011 46 892 898 10.1038/bmt.2010.197 20711243
50. First-line therapy for chronic graft-versus-host disease that includes low-dose methotrexate is associated with a high response rate. Wang Y, Xu LP, Liu DH, Chen H, Chen YH, Han W, Liu KY, Huang XJ, Biol Blood Marrow Transplant 2009 15 505 511 10.1016/j.bbmt.2008.12.493 19285639
51. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang GB, et al. Biol Blood Marrow Transplant 2011 17 1 17 10.1016/j.bbmt.2010.05.011 20685255
52. Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Lai Y, Ma J, Schwarzenberger P, Li W, Cai Z, Zhou J, Peng Z, Yang J, Luo L, Luo J, et al. Bone Marrow Transplant 2009 43 61 67 10.1038/bmt.2008.265 18724395
53. Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease following Unrelated Donor Peripheral Blood Stem Cell Transplantation. Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z, Li W, Zou P, Hu Y, Xia L, Biol Blood Marrow Transplant 2011 doi:10.1016/j.bbmt.2011.09.005
54. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Ning H, Yang F, Jiang M, Hu L, Feng K, Zhang J, Yu Z, Li B, Xu C, Li Y, et al. Leukemia 2008 22 593 599 10.1038/sj.leu.2405090 18185520 (Pubitemid 351386730)
55. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Weng JY, Du X, Geng SX, Peng YW, Wang Z, Lu ZS, Wu SJ, Luo CW, Guo R, Ling W, et al. Bone Marrow Transplant 2010 45 1732 1740 10.1038/bmt.2010.195 20818445
56. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Zhao F, Zhang Y, Wang H, Jin M, He S, Shi Y, Guo Y, Blood 2011 117 1723 1733 10.1182/blood-2010-04-281659 21119110
57. Genetic variations in the mycophenolate mofetil target enzyme are associated with acute GVHD risk after related and unrelated hematopoietic cell transplantation. Cao W, Xiao H, Lai X, Luo Y, Shi J, Tan Y, Zheng W, He J, Xie W, Li L, et al. Biol Blood Marrow Transplant 2012 18 273 279 10.1016/j.bbmt.2011.06.014 21745452
58. Human umbilical cord blood-derived stromal cells, a new resource in the suppression of acute graft-versus-host disease in haploidentical stem cell transplantation in sublethally irradiated mice. Zhang C, Chen XH, Zhang X, Gao L, Kong PY, Peng XG, Liang X, Gong Y, Wang QY, J Biol Chem 2011 286 13723 13732 10.1074/jbc.M110.144691 21349838
59. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4 + CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Qian K, Liu M, Transfusion 2011 doi: 10.1111/j.1537-2995.2011.03448.x
60. CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Chen W, Li M, Li Z, Yan Z, Cheng H, Pan B, Cao J, Chen C, Zeng L, Xu K, Immunol Lett 2012 doi:10.1016/j.imlet.2012.01.015
61. Treating the "older" adult with acute lymphoblastic leukemia. Marks DI, Hematology Am Soc Hematol Educ Program 2010 2010 13 20 10.1182/asheducation-2010.1.13 21239765
62. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R, Giralt S, Blood 2007 109 1395 1400 10.1182/blood-2006-05-021907 17038533 (Pubitemid 46239569)
63. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Guo M, Hu KX, Yu CL, Sun QY, Qiao JH, Wang DH, Liu GX, Sun WJ, Wei L, Sun XD, et al. Blood 2011 117 936 941 10.1182/blood-2010-06-288506 20966170